Preventing diabetic complications: A primary care perspective

Paul Zimmet

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

While controlling cardiometabolic risk factors remains central to diabetes management, substantial disease burden persists despite intensive targeting of blood glucose, blood pressure and lipids. Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study provide some new insights. As well as significant reduction in total cardiovascular disease events, especially among patients with marked atherogenic dyslipidaemia (low high-density lipoprotein (HDL) cholesterol and hypertriglyceridaemia), fenofibrate had preventive effects on microvascular outcomes, reducing laser treatment for retinopathy, progression of albuminuria, and non-traumatic amputations. These findings suggest re-evaluation of fenofibrate as an option for reducing the risk of diabetic vascular complications.

LanguageEnglish
Pages107-116
Number of pages10
JournalDiabetes Research and Clinical Practice
Volume84
Issue number2
DOIs
Publication statusPublished - 1 May 2009

Keywords

  • Cardiometabolic risk factors
  • Diabetes
  • Diabetic retinopathy
  • Fenofibrate
  • Preventive medicine

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{6fa061808fa545a98d9a93318daf9813,
title = "Preventing diabetic complications: A primary care perspective",
abstract = "While controlling cardiometabolic risk factors remains central to diabetes management, substantial disease burden persists despite intensive targeting of blood glucose, blood pressure and lipids. Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study provide some new insights. As well as significant reduction in total cardiovascular disease events, especially among patients with marked atherogenic dyslipidaemia (low high-density lipoprotein (HDL) cholesterol and hypertriglyceridaemia), fenofibrate had preventive effects on microvascular outcomes, reducing laser treatment for retinopathy, progression of albuminuria, and non-traumatic amputations. These findings suggest re-evaluation of fenofibrate as an option for reducing the risk of diabetic vascular complications.",
keywords = "Cardiometabolic risk factors, Diabetes, Diabetic retinopathy, Fenofibrate, Preventive medicine",
author = "Paul Zimmet",
year = "2009",
month = "5",
day = "1",
doi = "10.1016/j.diabres.2009.01.016",
language = "English",
volume = "84",
pages = "107--116",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Preventing diabetic complications : A primary care perspective. / Zimmet, Paul.

In: Diabetes Research and Clinical Practice, Vol. 84, No. 2, 01.05.2009, p. 107-116.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Preventing diabetic complications

T2 - Diabetes Research and Clinical Practice

AU - Zimmet, Paul

PY - 2009/5/1

Y1 - 2009/5/1

N2 - While controlling cardiometabolic risk factors remains central to diabetes management, substantial disease burden persists despite intensive targeting of blood glucose, blood pressure and lipids. Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study provide some new insights. As well as significant reduction in total cardiovascular disease events, especially among patients with marked atherogenic dyslipidaemia (low high-density lipoprotein (HDL) cholesterol and hypertriglyceridaemia), fenofibrate had preventive effects on microvascular outcomes, reducing laser treatment for retinopathy, progression of albuminuria, and non-traumatic amputations. These findings suggest re-evaluation of fenofibrate as an option for reducing the risk of diabetic vascular complications.

AB - While controlling cardiometabolic risk factors remains central to diabetes management, substantial disease burden persists despite intensive targeting of blood glucose, blood pressure and lipids. Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study provide some new insights. As well as significant reduction in total cardiovascular disease events, especially among patients with marked atherogenic dyslipidaemia (low high-density lipoprotein (HDL) cholesterol and hypertriglyceridaemia), fenofibrate had preventive effects on microvascular outcomes, reducing laser treatment for retinopathy, progression of albuminuria, and non-traumatic amputations. These findings suggest re-evaluation of fenofibrate as an option for reducing the risk of diabetic vascular complications.

KW - Cardiometabolic risk factors

KW - Diabetes

KW - Diabetic retinopathy

KW - Fenofibrate

KW - Preventive medicine

UR - http://www.scopus.com/inward/record.url?scp=63649120214&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2009.01.016

DO - 10.1016/j.diabres.2009.01.016

M3 - Review article

VL - 84

SP - 107

EP - 116

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -